Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength? [Yahoo! Finance]
Foghorn Therapeutics Inc. (FHTX)
Company Research
Source: Yahoo! Finance
This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 43.2% gain over the past four weeks. Last month, the company announced robust financial results for the second quarter of 2024. Studies on the company's pipeline candidates for treating various oncology indications are progressing well. This might have been driving the share price rally. This company is expected to post quarterly loss of $0.41 per share in its upcoming report, which represents a year-over-year change of -20.6%. Revenues are expected to be $7.01 million, down 59.9% from the year-ago quarter. Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements. For Foghorn Therapeutics, the consensus EPS estimate for the quarter has been revised 7%
Show less
Read more
Impact Snapshot
Event Time:
FHTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FHTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FHTX alerts
High impacting Foghorn Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
FHTX
News
- Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech IndustryPR Newswire
- Foghorn Therapeutics Inc. (NASDAQ: FHTX) had its price target raised by analysts at Morgan Stanley from $6.00 to $9.00. They now have an "equal weight" rating on the stock.MarketBeat
- Foghorn Therapeutics Inc. (NASDAQ: FHTX) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $18.00 price target on the stock.MarketBeat
- Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business OfficerGlobeNewswire
- Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in SeptemberGlobeNewswire
FHTX
Earnings
- 8/8/24 - Beat
FHTX
Sec Filings
- 9/24/24 - Form 4
- 9/20/24 - Form SC
- 9/20/24 - Form 4
- FHTX's page on the SEC website